Literature DB >> 22426579

Limited end-user knowledge of methotrexate despite patient education: an assessment of rheumatologic preventive practice and effectiveness.

Evin Sowden1, Wajid Hassan, Ann Gooden, Bridget Jepson, Tamsheela Kausor, Ifraz Shafait, Sahena Haque, John E Brockbank, Robert W Ley, Lee-Suan Teh.   

Abstract

BACKGROUND: Methotrexate (MTX) is a first-line disease-modifying agent and anchor drug for biologic therapy used in rheumatoid arthritis and other inflammatory rheumatic disorders. Adverse effects are a common cause of drug discontinuation and include preventable serious incidents that may result in patient harm or death.
OBJECTIVES: The objective of this study was to audit adherence by health professionals to national and international guidelines for patient education and risk reduction in patients prescribed MTX for inflammatory rheumatic diseases.
METHODS: A combination of interviews, case record reviews, and self-administered patient knowledge questionnaires with individual patient feedback was used. The setting was the rheumatology outpatient department of a district general hospital.
RESULTS: Fifty-one patients participated in the audit. The mean age was 58.6 (SD, 13.1) years and median duration of disease was 3.7 years (interquartile range, 1.7-7.6 years). Nurse-led patient education was documented at baseline for 94.1% of participants. Despite this, only 11.8% of participants recognized the potentially lethal drug-drug interaction with trimethoprim/Septrin (co-trimoxazole), and less than 60.8% recognized possible major adverse effects related to MTX. Although lifestyle implications relating to alcohol consumption and pregnancy/breast-feeding were recognized by the majority, only 52.9% of males were aware of recommendations in relation to conception. Univariable and multivariable analyses identified male sex, not speaking English as a first language, and a longer duration of therapy as predictors of lower levels of patient knowledge.
CONCLUSIONS: Despite consistent baseline patient education, end-user knowledge and awareness pertinent to MTX safety are limited. Good-quality written information in the most appropriate language, patient feedback on educational programs, follow-up testing of patient knowledge, and targeted reeducation are recommended to address individual deficiencies in core knowledge.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426579     DOI: 10.1097/RHU.0b013e31824e1e63

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  4 in total

Review 1.  Medication Risk Communication in Rheumatology: Where Are We and Where Do We Go from Here?

Authors:  Susan J Blalock
Journal:  Curr Rheumatol Rep       Date:  2017-02       Impact factor: 4.592

2.  Therapeutic education improves rheumatoid arthritis patients' knowledge about methotrexate: a single center retrospective study.

Authors:  Francoise Fayet; Bruno Pereira; Angelique Fan; Malory Rodere; Carine Savel; Pauline Berland; Martin Soubrier; Anne Tournadre; Jean Jacques Dubost
Journal:  Rheumatol Int       Date:  2021-05-29       Impact factor: 2.631

3.  Patient experiences, attitudes and expectations towards receiving information about anti-TNF medication: a quantitative study.

Authors:  Jon Packham; Paul Arkell; Tom Sheeran; Ann Brownfield; Anthony Cadwgan; Sarah Ryan
Journal:  Clin Rheumatol       Date:  2017-05-19       Impact factor: 2.980

4.  Poor knowledge of methotrexate associated with older age and limited English-language proficiency in a diverse rheumatoid arthritis cohort.

Authors:  Jennifer L Barton; Gabriela Schmajuk; Laura Trupin; Jonathan Graf; John Imboden; Edward H Yelin; Dean Schillinger
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.